The Journal of Allergy and Clinical Immunology
Volume 100, Issue 3 , Pages 301-306, September 1997

The safety of asthma and allergy medications during pregnancy☆☆★★

San Diego, Calif.

Received 8 July 1996; received in revised form 14 February 1997; accepted 24 March 1997.

Abstract 

Background: Although no asthma or allergy medications can be considered proven safe for use during pregnancy, these medications are often used to prevent the potential direct and indirect consequences of uncontrolled asthma or allergy. Objective: The safety of asthma medications, antihistamines, and decongestants was assessed in a prospectively monitored cohort of 824 pregnant women with and 678 pregnant women without asthma. Methods: Medications used since conception were recorded on each subject's initial visit (< 28 weeks' gestation). Thereafter, diary cards for medications were completed by the patient through the time of delivery. Perinatal outcomes were compared in exposed versus unexposed individuals. A multivariate analysis accounted for the potential effects of age, parity, smoking, race, weight gain during pregnancy, maternal pulmonary function, acute asthmatic episodes, and multiple medication exposure. Results: No significant relationships were identified between major congenital malformations and first trimester or any exposure to β-agonists, theophylline, cromolyn, corticosteroids, antihistamines, or decongestants. In the multivariate analyses, oral corticosteroids were independently associated with preeclampsia (odds ratio = 2.0, p = 0.027), but no other independent associations were observed between asthma or allergy medications and adverse perinatal outcomes. Conclusion: Use of most common asthma and allergy medications during pregnancy was not associated with increased perinatal risks. Maternal use of oral corticosteroids was independently associated with the occurrence of preeclampsia in this study, although the mechanism of this association is not clear. However, because prior observations suggest that severe asthma may be associated with maternal and/or fetal mortality, risk-benefit considerations still favor the use of oral corticosteroids when indicated for the treatment of asthma during pregnancy. (J Allergy Clin Immunol 1997;100:301-6.)

Keywords:  pregnancy, medications, corticosteroids, preeclampsia, asthma, allergy

 

 From the Departments of Allergy, Obstetrics and Gynecology, and Research and Evaluation, Kaiser-Permanente Medical Center, San Diego.

☆☆ Supported in part by Grant No. AI 20426 fron the Asthma and Allergy Branch of the National Institiute of Allergy and Infectious Diseases and a grant fron the Kaiser Foundation Hospital Research Foundation.

 Reprint requests: Michael Schatz, MD, Department of Allergy, Kaiser-Permanente Medical Center, 7060 Clairemont Mesa Blvd., San Diego, CA 92111.

★★ 1/1/82146

PII: S0091-6749(97)70241-0

The Journal of Allergy and Clinical Immunology
Volume 100, Issue 3 , Pages 301-306, September 1997